Clinical trials: Inappropriate ADH Syndrome
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
Tolvaptan Versus Fluid Restriction in SIADH
Context. The relevance of hyponatremia has been acknowledged by guidelines from the United States of America (2013) and Europe (2014). However, treatment recommendations differ due to limited evidence. Objective.
- Conditions
- Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion, Pituitary
- Trial name
- NCT04119206
- Volunteers
- 334 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Electrolyte Disturbances, Subarachnoid Hemorrhage
Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury
During the course of their acute illness patients with subarachnoid hemorrhage and severe traumatic brain injury often develop disturbances in their fluid balance and electrolyte homeostasis.
- Conditions
- Electrolyte Disturbances, Subarachnoid Hemorrhage, Traumatic Brain Injury, Natriuretic Peptides
- Trial name
- NCT01313975
- Where
- Switzerland
- Volunteers
- 85 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hyponatremia, SIADH
Low-dose Tolvaptan for Inpatient Hyponatraemia.
This is a retrospective cohort study to assess the safety and efficacy of low first dose of Tolvaptan and low or standard second dose of Tolvaptan in patients with moderate to severe hyponatraemia associated with SIADH not…
- Trial name
- NCT06171100
- Testing
- Tolvaptan
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- King's College Hospital NHS Trust
Hyponatremia, Inappropriate ADH Syndrome
Urea for Chronic Hyponatremia
This study is examining how a dietary supplement called urea can be used to treat low blood sodium level. Low blood sodium level is a common problem and some studies show that many patients with low blood sodium level suffer from…
- Trial name
- NCT04588207
- Testing
- Urea
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Helbert Rondon Berrios, MD, MS
Antidiuretic Hormone, Inappropriate Secretion
Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH
The purpose of this study is to confirm the safety of tolvaptan in patients with hyponatremia in syndrome of inappropriate antidiuretic hormone secretion (SIADH) in Japan
- Trial name
- NCT04790175
- Testing
- Tolvaptan (SAMSCA)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD
Hyponatremia is a common electrolyte imbalance which often results from hormonal disregulation. The study aims to investigate whether the apelin hormone, which plays a role in regulating salt and water balance in the body, can be…
- Trial name
- ESCAPE (NCT06277336)
- Testing
- Apelin Low Dose, Apelin High Dose, Selected Apelin Dose
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia
Subclassification of the Syndrome of Inappropriate ADH Secretion
The aim of this study is to evaluate the different types of osmotic dysregulation in patients with Syndrome of Inappropriate ADH (SIADH) and, hence, to analyze the pathophysiology of SIADH.
- Trial name
- NCT01341665
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wuerzburg
Syndrome of Inappropriate Antidiuresis (SIAD)
Effect of Protein Supplementation on Plasma Sodium Levels and Urinary Urea Excretion in Patients With SIAD
This study aims to investigate whether a 7-day dietary high protein supplementation of 90 grams per day increases plasma sodium levels in hyponatremic patients with chronic SIAD.
- Trial name
- TREASURE (NCT04987385)
- Testing
- Protein supplementation, Oral urea
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia, SIADH
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
This study seeks to investigate if hyponatraemia be a direct contributor to death in schizophrenic and bipolar patients, and gauge the potential role of somatic comorbidity and psychotropic polypharmacy, with emphasis on…
- Trial name
- NCT04409626
- Testing
- Plasma sodium level (continuous variables)
- Volunteers
- 31,740 people
- Sponsor
- Zealand University Hospital
Hyponatremia, Inappropriate ADH Syndrome
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
The primary objective of this study is to assess the efficacy of satavaptan versus placebo in participants with dilutional hyponatremia due to SIADH.
- Trial name
- AQUARIST1 (NCT00728091)
- Testing
- Satavaptan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sanofi
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia
Study of Ascending Levels of Tolvaptan in Hyponatremia
The purpose of this study was to determine whether tolvaptan can safely and effectively return the body's balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this…
- Trial name
- SALT2 (NCT00201994)
- Testing
- Tolvaptan
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hyponatremia, Hypovolemia
Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia
Retrospective study that analyzes the changes in serum creatinine as a tool to correctly classify the volemic status volemic status (euvolemia vs hypovolemia) of the patients with hyponatremia.
- Conditions
- Hyponatremia, Hypovolemia, SIADH
- Trial name
- NCT04744987
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital San Carlos, Madrid
Hyponatremia, Dilutional Hyponatremia
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction.
- Conditions
- Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
- Trial name
- SALACIA (NCT01227512)
- Testing
- tolvaptan, Fluid Restriction
- Where
- 56 sites in United States
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Hyponatremia, Syndrome of Inappropriate Antidiuresis
Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis
The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.
- Trial name
- TREASUREx (NCT06821802)
- Testing
- Moltein PURE Protein Powder, Fluid restriction
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- University Hospital, Basel, Switzerland
Asymptomatic Bacteriuria, Frailty
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
The population is aging. Aged people are more prown to develop frailty. The causes of frailty are multifactorial and are being investigated in research settings.
- Conditions
- Asymptomatic Bacteriuria, Frailty, Geriatric Syndrome, SIADH
- Trial name
- NCT05055856
- Testing
- urine sample, Blood and urine sample
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
This is a study to evaluate how the body handles and metabolizes (PK) the various doses of the drug Tolvaptan, and what the effect (PD) of the various doses of Tolvaptan are on the content of "salt" in blood and urine
- Trial name
- NCT02009878
- Testing
- tolvaptan
- Where
- 14 sites in Czechia, Denmark and 5 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water retention and secondary natriuresis and is a common cause for…
- Trial name
- SANDx (NCT03202667)
- Testing
- Empagliflozin 25mg
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Basel, Switzerland
Hyponatremia, SIADH
Tolvaptan for Patients With Acute Neurological Injuries
Hyponatremia occurs frequently in patients with acute brain injury in the days to weeks following injury, and may contribute to adverse outcome.
- Trial name
- NCT02545114
- Testing
- Tolvaptan
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Polderman, Kees, H., MD, PhD